Mitchell Ho (M Ho)

Publication Activity (10 Years)

Years Active: 2017-2024
Publications (10 Years): 51

Top Topics

Helicobacter Pylori Infection

Top Venues

Proceedings of the National Academy of Sciences of the United States of America

Nature communications

Nature reviews. Cancer

Antibody therapeutics

This page only lists publications with an associated author ORCID identifier.

Publications

Jason Gorman, Crystal Sao-Fong Cheung, Zhijian Duan, Li Ou, Maple Wang, Xuejun Chen, Cheng Cheng, Andrea Biju, Yaping Sun, Pengfei Wang, Yongping Yang, Baoshan Zhang, Jeffrey C Boyington, Tatsiana Bylund, Sam Charaf, Steven J Chen, Haijuan Du, Amy R Henry, Tracy Liu, Edward K Sarfo, Chaim A Schramm, Chen-Hsiang Shen, Tyler Stephens, I-Ting Teng, John-Paul Todd, Yaroslav Tsybovsky, Raffaello Verardi, Danyi Wang, Shuishu Wang, Zhantong Wang, Cheng-Yan Zheng, Tongqing Zhou, Daniel C Douek, John R Mascola, David D Ho, Mitchell Ho, Peter D Kwong
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nature communications 15 (1) (2024)
Jason Gorman, Crystal Sao-Fong Cheung, Zhijian Duan, Li Ou, Maple Wang, Xuejun Chen, Cheng Cheng, Andrea Biju, Yaping Sun, Pengfei Wang, Yongping Yang, Baoshan Zhang, Jeffrey C Boyington, Tatsiana Bylund, Sam Charaf, Steven J Chen, Haijuan Du, Amy R Henry, Tracy Liu, Edward K Sarfo, Chaim A Schramm, Chen-Hsiang Shen, Tyler Stephens, I-Ting Teng, John-Paul Todd, Yaroslav Tsybovsky, Raffaello Verardi, Danyi Wang, Shuishu Wang, Zhantong Wang, Cheng-Yan Zheng, Tongqing Zhou, Daniel C Douek, John R Mascola, David D Ho, Mitchell Ho, Peter D Kwong
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nature communications 15 (1) (2024)
X F Liu, M Onda, J Schlomer, Laura L Bassel, S Kozlov, C-H Tai, Q Zhou, Wenlong Liu, H-E Tsao, R Hassan, Mitchell Ho, Ira H Pastan
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
Jason Gorman, Crystal Sao-Fong Cheung, Zhijian Duan, Li Ou, Maple Wang, Xuejun Chen, Cheng Cheng, Andrea Biju, Yaping Sun, Pengfei Wang, Yongping Yang, Baoshan Zhang, Jeffrey C Boyington, Tatsiana Bylund, Sam Charaf, Steven J Chen, Haijuan Du, Amy R Henry, Tracy Liu, Edward K Sarfo, Chaim A Schramm, Chen-Hsiang Shen, Tyler Stephens, I-Ting Teng, John-Paul Todd, Yaroslav Tsybovsky, Raffaello Verardi, Danyi Wang, Shuishu Wang, Zhantong Wang, Cheng-Yan Zheng, Tongqing Zhou, Daniel C Douek, John R Mascola, David D Ho, Mitchell Ho, Peter D Kwong
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nature communications 15 (1) (2024)
X F Liu, M Onda, J Schlomer, Laura L Bassel, S Kozlov, C-H Tai, Q Zhou, Wenlong Liu, H-E Tsao, R Hassan, Mitchell Ho, Ira H Pastan
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
Suman Paul, Maximilian Ferdinand Konig, Drew M Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M Wright, Sandra B Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
Cancer therapy with antibodies. Nature reviews. Cancer 24 (6) (2024)
Suman Paul, Maximilian Ferdinand Konig, Drew M Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M Wright, Sandra B Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
Cancer therapy with antibodies. Nature reviews. Cancer 24 (6) (2024)
X F Liu, M Onda, J Schlomer, Laura L Bassel, S Kozlov, C-H Tai, Q Zhou, Wenlong Liu, H-E Tsao, R Hassan, Mitchell Ho, Ira H Pastan
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
X F Liu, M Onda, J Schlomer, Laura L Bassel, S Kozlov, C-H Tai, Q Zhou, Wenlong Liu, H-E Tsao, R Hassan, Mitchell Ho, Ira H Pastan
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
X F Liu, M Onda, J Schlomer, Laura L Bassel, S Kozlov, C-H Tai, Q Zhou, Wenlong Liu, H-E Tsao, R Hassan, Mitchell Ho, Ira H Pastan
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
Dan Li, Tianyuzhou Liang, Laura E Hutchins, Alexandra A Wolfarth, Sara Ferrando-Martinez, Byung Ha Lee, Mitchell Ho
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. Journal for immunotherapy of cancer 12 (7) (2024)
Jason Gorman, Crystal Sao-Fong Cheung, Zhijian Duan, Li Ou, Maple Wang, Xuejun Chen, Cheng Cheng, Andrea Biju, Yaping Sun, Pengfei Wang, Yongping Yang, Baoshan Zhang, Jeffrey C Boyington, Tatsiana Bylund, Sam Charaf, Steven J Chen, Haijuan Du, Amy R Henry, Tracy Liu, Edward K Sarfo, Chaim A Schramm, Chen-Hsiang Shen, Tyler Stephens, I-Ting Teng, John-Paul Todd, Yaroslav Tsybovsky, Raffaello Verardi, Danyi Wang, Shuishu Wang, Zhantong Wang, Cheng-Yan Zheng, Tongqing Zhou, Daniel C Douek, John R Mascola, David D Ho, Mitchell Ho, Peter D Kwong
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nature communications 15 (1) (2024)
Suman Paul, Maximilian Ferdinand Konig, Drew M Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M Wright, Sandra B Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
Cancer therapy with antibodies. Nature reviews. Cancer 24 (6) (2024)
Suman Paul, Maximilian Ferdinand Konig, Drew M Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M Wright, Sandra B Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
Cancer therapy with antibodies. Nature reviews. Cancer 24 (6) (2024)
Jason Gorman, Crystal Sao-Fong Cheung, Zhijian Duan, Li Ou, Maple Wang, Xuejun Chen, Cheng Cheng, Andrea Biju, Yaping Sun, Pengfei Wang, Yongping Yang, Baoshan Zhang, Jeffrey C Boyington, Tatsiana Bylund, Sam Charaf, Steven J Chen, Haijuan Du, Amy R Henry, Tracy Liu, Edward K Sarfo, Chaim A Schramm, Chen-Hsiang Shen, Tyler Stephens, I-Ting Teng, John-Paul Todd, Yaroslav Tsybovsky, Raffaello Verardi, Danyi Wang, Shuishu Wang, Zhantong Wang, Cheng-Yan Zheng, Tongqing Zhou, Daniel C Douek, John R Mascola, David D Ho, Mitchell Ho, Peter D Kwong
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nature communications 15 (1) (2024)
X F Liu, M Onda, J Schlomer, Laura L Bassel, S Kozlov, C-H Tai, Q Zhou, Wenlong Liu, H-E Tsao, R Hassan, Mitchell Ho, Ira H Pastan
Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proceedings of the National Academy of Sciences of the United States of America 121 (4) (2024)
Dan Li, Tianyuzhou Liang, Laura E Hutchins, Alexandra A Wolfarth, Sara Ferrando-Martinez, Byung Ha Lee, Mitchell Ho
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. Journal for immunotherapy of cancer 12 (7) (2024)
Suman Paul, Maximilian Ferdinand Konig, Drew M Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M Wright, Sandra B Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
Cancer therapy with antibodies. Nature reviews. Cancer 24 (6) (2024)
Dan Li, Tianyuzhou Liang, Laura E Hutchins, Alexandra A Wolfarth, Sara Ferrando-Martinez, Byung Ha Lee, Mitchell Ho
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumors. Journal for immunotherapy of cancer 12 (7) (2024)
Suman Paul, Maximilian Ferdinand Konig, Drew M Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M Wright, Sandra B Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
Cancer therapy with antibodies. Nature reviews. Cancer (2024)
Suman Paul, Maximilian Ferdinand Konig, Drew M Pardoll, Chetan Bettegowda, Nickolas Papadopoulos, Katharine M Wright, Sandra B Gabelli, Mitchell Ho, Andrea van Elsas, Shibin Zhou
Cancer therapy with antibodies. Nature reviews. Cancer (2024)
Jason Gorman, Crystal Sao-Fong Cheung, Zhijian Duan, Li Ou, Maple Wang, Xuejun Chen, Cheng Cheng, Andrea Biju, Yaping Sun, Pengfei Wang, Yongping Yang, Baoshan Zhang, Jeffrey C Boyington, Tatsiana Bylund, Sam Charaf, Steven J Chen, Haijuan Du, Amy R Henry, Tracy Liu, Edward K Sarfo, Chaim A Schramm, Chen-Hsiang Shen, Tyler Stephens, I-Ting Teng, John-Paul Todd, Yaroslav Tsybovsky, Raffaello Verardi, Danyi Wang, Shuishu Wang, Zhantong Wang, Cheng-Yan Zheng, Tongqing Zhou, Daniel C Douek, John R Mascola, David D Ho, Mitchell Ho, Peter D Kwong
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability. Nature communications 15 (1) (2024)
Nan Li, Alex Quan, Dan Li, Jiajia Pan, Hua Ren, Gerard Hoeltzel, Natalia de Val, Dana Ashworth, Weiming Ni, Jing Zhou, Sean Mackay, Stephen M Hewitt, Raul E Cachau, Mitchell Ho
The IgG4 hinge with CD28 transmembrane domain improves V H H-based CAR T cells targeting a membrane-distal epitope of GPC1 in pancreatic cancer. Nature communications 14 (1) (2023)
Dan Li, Ruixue Wang, Tianyuzhou Liang, Hua Ren, Chaelee Park, Chin-Hsien Tai, Weiming Ni, Jing Zhou, Sean Mackay, Elijah F Edmondson, Javed Khan, Brad St Croix, Mitchell Ho
Camel nanobody-based B7-H3 CAR-T cells show high efficacy against large solid tumours. Nature communications 14 (1) (2023)
Aarti Kolluri, Dan Li, Nan Li, Zhijian Duan, Lewis Rowland Roberts, Mitchell Ho
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC. Hepatology communications 7 (2) (2023)
Aarti Kolluri, Dan Li, Nan Li, Zhijian Duan, Lewis Rowland Roberts, Mitchell Ho
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC. Hepatology communications 7 (2) (2023)
Aarti Kolluri, Dan Li, Nan Li, Zhijian Duan, Lewis Rowland Roberts, Mitchell Ho
Human VH-based chimeric antigen receptor T cells targeting glypican 3 eliminate tumors in preclinical models of HCC. Hepatology communications 7 (2) (2023)
Matthew Bell, Shannon Lange, Besian I Sejdiu, Jorge Ibañez-Vega, Hao Shi, Xiang Sun, Xiaoxi Meng, Phuong Nguyen, Morgan Sutton, Jessica Wagner, Anil Kc, Deanna M Langfitt, Sagar L Patil, Haiyan Tan, Ram Vinay Pandey, Yuxin Li, Zuo-Fei Yuan, Alejandro Allo Anido, Mitchell Ho, Heather Sheppard, Peter Vogel, Jiyang Yu, Junmin Peng, Hongbo Chi, M Madan Babu, Giedre Krenciute, Stephen Gottschalk
Modular chimeric cytokine receptors with leucine zippers enhance the antitumour activity of CAR T cells via JAK/STAT signalling. Nature biomedical engineering (2023)
Rosa Nguyen, Ekaterina Doubrovina, Charlotte M Mousset, Benjamin Y Jin, Reona Okada, Xiyuan Zhang, Arina Clavel, Jeyshka M Reyes-González, Vadim Dyomin, Louis Diaz, Ling Zhang, Shahroze Abbas, Ming Sun, Chao-Ming Hsieh, Mitchell Ho, Jack F Shern, James L Gulley, Christian S Hinrichs
Cooperative armoring of CAR and TCR T-cells by T cell-restricted IL-15 and IL-21 universally enhances solid tumor efficacy. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Jesse Buffington, Zhijian Duan, Hyung Joon Kwon, Jessica Hong, Dan Li, Mingqian Feng, Hang Xie, Mitchell Ho
Identification of nurse shark V NAR single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 37 (6) (2023)
Jessica Hong, Hyung Joon Kwon, Raul Cachau, Catherine Z Chen, Kevin John Butay, Zhijian Duan, Dan Li, Hua Ren, Tianyuzhou Liang, Jianghai Zhu, Venkata P Dandey, Negin P Martin, Dominic Esposito, Uriel Ortega-Rodriguez, Miao Xu, Mario Juan Borgnia, Hang Xie, Mitchell Ho
Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants. Proceedings of the National Academy of Sciences of the United States of America 119 (18) (2022)
Yong Zhu, Shawn Shouye Wang, Zhaohui Sunny Zhou, Mitchell Ho
The emergence of AntibodyPlus: the future trend of antibody-based therapeutics. Antibody therapeutics 5 (4) (2022)
Jiajia Pan, Nan Li, Alex Renn, Hu Zhu, Lu Chen, Min Shen, Matthew D Hall, Min Qian, Ira H Pastan, Mitchell Ho
GPC1-Targeted Immunotoxins Inhibit Pancreatic Tumor Growth in Mice via Depletion of Short-lived GPC1 and Downregulation of Wnt Signaling. Molecular cancer therapeutics 21 (6) (2022)
Bryan D Fleming, Mitchell Ho
Generation of Single-Domain Antibody-Based Recombinant Immunotoxins. Methods in molecular biology (Clifton, N.J.) 2446 (2022)
Sakshi Tomar, Jingli Zhang, Manakamana Khanal, Jessica Hong, Abhilash Venugopalan, Qun Jiang, Manjistha Sengupta, Markku M Miettinen, Nan Li, Ira H Pastan, Mitchell Ho, Raffit Hassan
Development of Highly Effective Anti-Mesothelin hYP218 Chimeric Antigen Receptor T Cells With Increased Tumor Infiltration and Persistence for Treating Solid Tumors. Molecular cancer therapeutics 21 (7) (2022)
Xiufen Liu, Masanori Onda, Nathan Watson, Raffit Hassan, Mitchell Ho, Tapan K Bera, Junxia Wei, Anirban Chakraborty, Richard Beers, Qi Zhou, Asif Shajahan, Parastoo Azadi, Jingyu Zhan, Di Xia, Ira H Pastan
Highly active CAR T cells that bind to a juxtamembrane region of mesothelin and are not blocked by shed mesothelin. Proceedings of the National Academy of Sciences of the United States of America 119 (19) (2022)
Zhijian Duan, Mitchell Ho
T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy. Molecular cancer therapeutics 20 (9) (2021)
Zhijian Duan, Mitchell Ho
Targeting the cancer neoantigens p53 and KRAS with TCR mimic antibodies. Antibody therapeutics 4 (4) (2021)
Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho, Mingqian Feng
Combination Therapy of Hepatocellular Carcinoma by GPC3-Targeted Bispecific Antibody and Irinotecan is Potent in Suppressing Tumor Growth in Mice. Molecular cancer therapeutics (2021)
Jiajia Pan, Mitchell Ho
Role of glypican-1 in regulating multiple cellular signaling pathways. American journal of physiology. Cell physiology 321 (5) (2021)
Jessica Hong, Hyung Joon Kwon, Raul Cachau, Catherine Z Chen, Kevin John Butay, Zhijian Duan, Dan Li, Hua Ren, Tianyuzhou Liang, Jianghai Zhu, Venkata P Dandey, Negin Martin, Dominic Esposito, Uriel Ortega-Rodriguez, Miao Xu, Mario J Borgnia, Hang Xie, Mitchell Ho
Camel nanobodies broadly neutralize SARS-CoV-2 variants. bioRxiv : the preprint server for biology (2021)
Ramin Dubey, Peter van Kerkhof, Ingrid Jordens, Tomas Malinauskas, Ganesh V Pusapati, Joseph K McKenna, Dan Li, Jan E Carette, Mitchell Ho, Christian Siebold, Madelon Maurice, Andres M Lebensohn, Rajat Rohatgi
R-spondins engage heparan sulfate proteoglycans to potentiate WNT signaling. eLife 9 (2020)
Bryan D Fleming, Mitchell Ho
Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update. Biomolecules 10 (6) (2020)
Lifei Yang, Weihan Liu, Xin Yu, Meng Wu, Janice M Reichert, Mitchell Ho
COVID-19 antibody therapeutics tracker: a global online database of antibody therapeutics for the prevention and treatment of COVID-19. Antibody therapeutics 3 (3) (2020)
Bryan D Fleming, Daniel J Urban, Matthew D Hall, Thomas Longerich, Tim F Greten, Ira Pastan, Mitchell Ho
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention. Hepatology (Baltimore, Md.) 71 (5) (2020)
Yaping Sun, Mitchell Ho
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic. Antibody therapeutics 3 (4) (2020)
Ying Fu, Daniel J Urban, Roger R Nani, Yi-Fan Zhang, Nan Li, Haiying Fu, Hamzah Shah, Alexander P Gorka, Rajarshi Guha, Lu Chen, Matthew D Hall, Martin J Schnermann, Mitchell Ho
Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma. Hepatology (Baltimore, Md.) 70 (2) (2019)
Na Li, Liwen Wei, Xiaoyu Liu, Hongjun Bai, Yvonne Ye, Dan Li, Nan Li, Ulrich Baxa, Qun Wang, Ling Lv, Yun Chen, Mingqian Feng, Byungkook Lee, Wei Gao, Mitchell Ho
A Frizzled-Like Cysteine-Rich Domain in Glypican-3 Mediates Wnt Binding and Regulates Hepatocellular Carcinoma Tumor Growth in Mice. Hepatology (Baltimore, Md.) 70 (4) (2019)
Junxia Wei, Tapan K Bera, Xiu Fen Liu, Qi Zhou, Masanori Onda, Mitchell Ho, Chin-Hsien Tai, Ira Pastan
Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity. Proceedings of the National Academy of Sciences of the United States of America 115 (15) (2018)
Ying Fu, Mitchell Ho
DNA damaging agent-based antibody-drug conjugates for cancer therapy. Antibody therapeutics 1 (2) (2018)
Nan Li, Haiying Fu, Stephen M Hewitt, Dimiter S Dimitrov, Mitchell Ho
Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma. Proceedings of the National Academy of Sciences of the United States of America 114 (32) (2017)